Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford Progeria Syndrome (HGPS)

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Plasilova, Martina ^a   Chattopadhyay, Chandon ^b,c   Ghosh, Apurba ^b   Wenzel, Friedel ^a   Demougin, Philippe ^d   Noppen, Christoph ^e   Schaub, Nathalie ^a   Szinnai, Gabor ^a   Terracciano, Luigi ^d   Heinimann, Karl ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b INSTITUTE OF CHILD HEALTH   (India)

^c SB Devi Charity Home   (India)

^d UNIVERSITY OF BASEL   (Switzerland)

^e Viollier AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIN A; LAMIN C; OSTEOCALCIN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; LMNA PROTEIN, HUMAN; OSTEOPROTEGERIN; PHOSPHODIESTERASE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR TWIST; TWIST2 PROTEIN, HUMAN;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE REMODELING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENPP 1 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; LMNA GENE; MOLECULAR DYNAMICS; OPG GENE; PATHOGENESIS; PHENOTYPIC VARIATION; PROGERIA; SENESCENCE; TRANSCRIPTION INITIATION; TWIST 2 GENE; ADULT; CELL CULTURE; CHILD; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

BLOTTING, WESTERN; CELLS, CULTURED; CHILD; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; LAMIN TYPE A; MALE; OSTEOPROTEGERIN; PHOSPHORIC DIESTER HYDROLASES; PROGERIA; PYROPHOSPHATASES; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; TWIST TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 79959624914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021433     Document Type: Article

References (86)

1. Worman HJ, Bonne G, (2007) "Laminopathies"ide spectrum of human diseases. Exp Cell Res 313: 2121-2133.
2. Hennekam RC, (2006) Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 140: 2603-2624.
3. Pereira S, Bourgeois P, Navarro C, Esteves-Vieira V, Cau P, et al. (2008) HGPS and related premature aging disorders: from genomic identification to the first therapeutic approaches. Mech Ageing Dev 129: 449-459.
4. Plasilova M, Chattopadhyay C, Pal P, Schaub NA, Buechner SA, et al. (2004) Homozygous missense mutation in the lamin A/C gene causes autosomal recessive Hutchinson-Gilford progeria syndrome. J Med Genet 41: 609-614.
5. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, et al. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358: 592-604.
6. Rusinol AE, Sinensky MS, (2006) Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 119: 3265-3272.
7. Herrmann H, Aebi U, (2004) Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular Scaffolds. Annu Rev Biochem 73: 749-789.
8. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL, (2005) The nuclear lamina comes of age. Nat Rev Mol Cell Biol 6: 21-31.
9. Herrmann H, Strelkov SV, Burkhard P, Aebi U, (2009) Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772-1783.
10. Broers JL, Machiels BM, Kuijpers HJ, Smedts F, van den Kieboom R, et al. (1997) A- and B-type lamins are differentially expressed in normal human tissues. Histochem Cell Biol 107: 505-517.
11. Stuurman N, Heins S, Aebi U, (1998) Nuclear lamins: their structure, assembly, and interactions. J Struct Biol 122: 42-66.
12. Melcer S, Gruenbaum Y, Krohne G, (2007) Invertebrate lamins. Exp Cell Res 313: 2157-2166.
13. Constantinescu D, Gray HL, Sammak PJ, Schatten GP, Csoka AB, (2006) Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. Stem Cells 24: 177-185.
14. Rober RA, Sauter H, Weber K, Osborn M, (1990) Cells of the cellular immune and hemopoietic system of the mouse lack lamins A/C: distinction versus other somatic cells. J Cell Sci 95 (Pt 4): 587-598.
15. Rober RA, Weber K, Osborn M, (1989) Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 105: 365-378.
16. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423: 293-298.
17. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, et al. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300: 2055.
18. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, et al. (2004) Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 101: 8963-8968.
19. Columbaro M, Capanni C, Mattioli E, Novelli G, Parnaik VK, et al. (2005) Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cell Mol Life Sci 62: 2669-2678.
20. Scaffidi P, Misteli T, (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11: 440-445.
21. Shumaker DK, Dechat T, Kohlmaier A, Adam SA, Bozovsky MR, et al. (2006) Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A 103: 8703-8708.
22. Liang L, Zhang H, Gu X, (2009) Homozygous LMNA mutation R527C in atypical Hutchinson-Gilford progeria syndrome: evidence for autosomal recessive inheritance. Acta Paediatr 98: 1365-1368.
23. Verstraeten VL, Broers JL, van Steensel MA, Zinn-Justin S, Ramaekers FC, et al. (2006) Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation. Hum Mol Genet 15: 2509-2522.
24. Cao H, Hegele RA, (2003) LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet 48: 271-274.
25. Lang C, Krohne G, (2003) Lamina-associated polypeptide 2beta (LAP2beta) is contained in a protein complex together with A- and B-type lamins. Eur J Cell Biol 82: 143-153.
26. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, et al. (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 102: 12879-12884.
27. Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, et al. (2008) Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 22: 832-853.
28. Csoka AB, English SB, Simkevich CP, Ginzinger DG, Butte AJ, et al. (2004) Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell 3: 235-243.
29. Wang J, Robinson JF, O'Neil CH, Edwards JY, Williams CM, et al. (2006) Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles. J Hum Genet 51: 934-942.
30. Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, et al. (2010) Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS ONE 5: e11132.
31. Bialek P, Kern B, Yang X, Schrock M, Sosic D, et al. (2004) A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423-435.
32. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN, (2003) Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112: 169-180.
33. Van Campenhout A, Golledge J, (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204: 321-329.
34. Golledge J, McCann M, Mangan S, Lam A, Karan M, (2004) Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35: 1636-1641.
35. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, et al. (2003) Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34: 379-381.
36. Maddux BA, Goldfine ID, (2000) Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 49: 13-19.
37. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, et al. (1995) Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 373: 448-451.
38. Olive M, Harten I, Mitchell R, Beers J, Djabali K, et al. (2010) Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular Pathology of Aging. Arterioscler Thromb Vasc Biol.
39. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, et al. (2003) Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18: 994-1004.
40. Wallace TM, Levy JC, Matthews DR, (2004) Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495.
41. Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, et al. (2004) What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 27: 2470-2477.
42. Cederholm J, Wibell L, (1990) Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10: 167-175.
43. Matsuda M, DeFronzo RA, (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
44. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469.
45. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, et al. (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9: 1273-1285.
46. Paradisi M, McClintock D, Boguslavsky RL, Pedicelli C, Worman HJ, et al. (2005) Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress. BMC Cell Biol 6: 27.
47. Wagner N, Krohne G, (2007) LEM-Domain proteins: new insights into lamin-interacting proteins. Int Rev Cytol 261: 1-46.
48. Wang Y, Panteleyev AA, Owens DM, Djabali K, Stewart CL, et al. (2008) Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin. Hum Mol Genet 17: 2357-2369.
49. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, et al. (2003) The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8: 645-654.
50. Yamaguchi TP, Bradley A, McMahon AP, Jones S, (1999) A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126: 1211-1223.
51. Person AD, Beiraghi S, Sieben CM, Hermanson S, Neumann AN, et al. (2010) WNT5A mutations in patients with autosomal dominant Robinow syndrome. Dev Dyn 239: 327-337.
52. Tukel T, Sosic D, Al-Gazali LI, Erazo M, Casasnovas J, et al. (2010) Homozygous nonsense mutations in TWIST2 cause Setleis syndrome. Am J Hum Genet 87: 289-296.
53. Baker PB, Baba N, Boesel CP, (1981) Cardiovascular abnormalities in progeria. Case report and review of the literature. Arch Pathol Lab Med 105: 384-386.
54. Stehbens WE, Wakefield SJ, Gilbert-Barness E, Olson RE, Ackerman J, (1999) Histological and ultrastructural features of atherosclerosis in progeria. Cardiovasc Pathol 8: 29-39.
55. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, et al. (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86: 273-278.
56. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM, (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86: 267-272.
57. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
58. Teitelbaum SL, Ross FP, (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649.
59. Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, et al. (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 18: 2095-2104.
60. Cundy T, Hegde M, Naot D, Chong B, King A, et al. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11: 2119-2127.
61. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, et al. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347: 175-184.
62. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, et al. (2007) Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 120: 824-833.
63. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM, (2005) Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 353: 918-923.
64. Rosenbloom AL, Kappy MS, DeBusk FL, Francis GL, Philpot TJ, et al. (1983) Progeria: insulin resistance and hyperglycemia. J Pediatr 102: 400-402.
65. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, et al. (2002) Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71: 426-431.
66. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, et al. (2000) LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24: 153-156.
67. Freidenberg GR, Cutler DL, Jones MC, Hall B, Mier RJ, et al. (1992) Severe insulin resistance and diabetes mellitus in mandibuloacral dysplasia. Am J Dis Child 146: 93-99.
68. Pollock NK, Bernard PJ, Wenger K, Misra S, Gower BA, et al. (2010) Lower bone mass in prepubertal overweight children with pre-diabetes. J Bone Miner Res.
69. Hwang YC, Jeong IK, Ahn KJ, Chung HY, (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25: 768-772.
70. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, et al. (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94: 45-49.
71. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B, (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94: 827-832.
72. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, et al. (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142: 309-319.
73. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, et al. (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142: 296-308.
74. Rosen CJ, Motyl KJ, (2010) No bones about it: insulin modulates skeletal remodeling. Cell 142: 198-200.
75. Motyl KJ, McCabe LR, Schwartz AV, (2010) Bone and glucose metabolism: a two-way street. Arch Biochem Biophys 503: 2-10.
76. Janghorbani M, Feskanich D, Willett WC, Hu F, (2006) Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29: 1573-1578.
77. Nicodemus KK, Folsom AR, (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24: 1192-1197.
78. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG, (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23: 295-303.
79. Gastaldelli A, Natali A, Vettor R, Corradini SG, (2010) Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig Liver Dis 42: 310-319.
80. Ferron M, Hinoi E, Karsenty G, Ducy P, (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 105: 5266-5270.
81. Hauschka PV, Lian JB, Cole DE, Gundberg CM, (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69: 990-1047.
82. Lee NK, Karsenty G, (2008) Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 19: 161-166.
83. Psarros M, Heber S, Sick M, Thoppae G, Harshman K, et al. (2005) RACE: Remote Analysis Computation for gene Expression data. Nucleic Acids Res 33: W638-643.
84. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
85. Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, et al. (2009) Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol.
86. Terracciano LM, Mhawech P, Suess K, D'Armiento M, Lehmann FS, et al. (2000) Calretinin as a marker for cardiac myxoma. Diagnostic and histogenetic considerations. Am J Clin Pathol 114: 754-759.